SCHEMBL23413601

SCHEMBL23413601

COc1scc(C)c1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 3/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KDM4E B2RXH2 2/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPT P10636 2/20 0.36
KMT2A Q03164 2/20 0.36
GAA P10253 1/20 0.36
G6PD P11413 1/20 0.36
MAPK1 P28482 1/20 0.36
RECQL P46063 1/20 0.36
MCL1 Q07820 1/20 0.36
MAPK8 P45983 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5154472 0.82 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL28664035 0.80 CA1 (0.39) CA12CA1CA2CA7CA9
SCHEMBL4236884 0.74 POLB (0.44) ALDH1A1POLBTDP1L3MBTL1KDM4E
SCHEMBL6492073 0.72 POLB (0.53) ALDH1A1POLBTDP1L3MBTL1KDM4E
SCHEMBL11013170 0.72 POLB (0.32) POLBMAPT
SCHEMBL190089 0.71 ALDH1A1 (0.41) ALDH1A1POLBTDP1L3MBTL1HSD17B10
SCHEMBL8304531 0.71 DAO (0.44) ALDH1A1POLBTDP1L3MBTL1KDM4E
SCHEMBL17398273 0.71 TSHR (0.47) ALDH1A1POLBTDP1L3MBTL1KDM4E
SCHEMBL8366102 0.71 L3MBTL1 (0.39) ALDH1A1POLBTDP1L3MBTL1KDM4E
SCHEMBL11232857 0.68 ALDH1A1 (0.53) CA1CA2ALDH1A1POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-09-05 US disclosed
US-20230065745-A1 PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF CAPTOR THERAPEUTICS S.A. (PL) 2023-03-02 US disclosed
WO-2021105335-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF CAPTOR THERAPEUTICS S.A. (PL) 2021-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN MCL1, MDM2, XIAP CA12 3684/4885CA1 3478/4885CA2 4467/4885
US-20230065745-A1 PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF CRBN, CDR2, FABP7 CA12 856/4885CA1 239/4885CA2 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.